miRNA-seq from liquid biopsy: robust detection from the lowest sample amounts

Jun 26, 2017 9:30 AM–10:30 AM (EST)
Duration: 1hrs
miRNAs impact virtually all areas of biology, and in circulation, they are promising biomarker candidates for both normal and disease biology. miRNAs are protected from degradation in virtually all biofluids by exosomes, Ago2, HDL or other protective proteins, but are expressed at low levels. As a result, expression analysis, particularly using next-generation sequencing (NGS), has proven to be difficult. Traditional small RNA library kits lack the sensitivity or specificity to adequately assess miRNA expression. Libraries prepared with using these kits have been fraught with background products, such as adapter dimers and other RNAs, including hY4 Y RNA. These problems collectively manifest as a low mapping percentage to miRNA, a limited dynamic range and lost discovery potential. QIAGEN’s QIAseq miRNA Library Kit is specifically designed to overcome these challenges. The innovative, gel-free workflow enables the preparation of robust libraries from even the most difficult, low RNA content biofluids. QIAseq miRNA maximizes your on-target miRNA reads, dynamic range and, mostly importantly, your discovery potential.

Jonathan Shaffer

Jonathan M. Shaffer
Dr. Shaffer joined QIAGEN in 2009 and has since worked with various technology development groups, the most recent being miRNA technologies. He received his Ph.D. in biochemistry and molecular genetics from the University of Pittsburgh School of Medicine in 2008 where his research focused on determining the mechanisms that regulate non-receptor tyrosine kinase expression and activity. Dr. Shaffer did his postdoctoral training at SABiosciences Corporation, now part of QIAGEN. Currently, Dr. Shaffer is a Scientist in R&D at QIAGEN.